Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia

OBJECTIVE: To report our clinical experience with bevacizumab in a cohort of Hereditary Hemorrhagic Telangiectasia (HHT) patients with severe hepatic involvement and/or refractory anemia. METHODS: Observational, ambispective study of the Institutional Registry of HHT at Hospital Italiano de Buenos A...

Descripción completa

Detalles Bibliográficos
Autores principales: Vázquez, Carolina, Gonzalez, María Laura, Ferraris, Augusto, Bandi, Juan Carlos, Serra, Marcelo Martín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006931/
https://www.ncbi.nlm.nih.gov/pubmed/32032395
http://dx.doi.org/10.1371/journal.pone.0228486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006931/
https://www.ncbi.nlm.nih.gov/pubmed/32032395
http://dx.doi.org/10.1371/journal.pone.0228486

Ejemplares similares